MONMOUTH JUNCTION, N.J. and
ATHENS, Ga., Feb. 22, 2021 /PRNewswire/ -- Tris Pharma,
Inc. ("Tris") and Athena Bioscience LLC ("Athena") announced today
that they have entered into an agreement by which Athena received
exclusive rights to commercialize a long-acting antihypertensive
product developed using Tris' proprietary technology.
On average, only 50% of adults adhere to chronic disease
medications1, and in the case of high blood pressure
(BP), lower levels of adherence are associated with worse BP
control and adverse outcomes, including stroke, myocardial
infarction, heart failure, and death 2-4. The licensed
product upon launch, will be the only once-daily formulation
containing an established Active Pharmaceutical Ingredient (API),
which physicians can optionally prescribe alone or concomitantly
with other antihypertensive agents to pursue desired outcomes.
"We are very happy to be partnering with Tris to bring this
unique product to patients," said Jeff
Bryant, CEO of Athena. "As the only once-daily of this
important API, it has the potential to improve both compliance and
adherence, which fits with our vision of delivering products to the
market that improve patient outcomes."
"This commercial collaboration supports our strategy of working
with partners to maximize the value of differentiated medications
developed with our technology platform.," said Ketan Mehta, Tris' Founder and CEO. "Given the
proven track record of Athena's leadership team to successfully
commercialize innovative medicines, we believe they are an
excellent partner to enable patient access to our transformative
technology."
About Tris Pharma
Tris Pharma is a New Jersey-based specialty pharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet patient needs. Tris has
used its innovative LiquiXR technology platform to develop its
portfolio of differentiated solid and liquid ADHD products
(described at www.TrisADHD.com), which it markets in the United States using its pediatric and
CNS-focused sales force. The company has leveraged its technology
platform to establish a robust product pipeline as well as numerous
mutually value-adding development partnerships. For more
information, please visit www.trispharma.com.
About Athena Bioscience
Athena Bioscience, LLC is
a specialty pharmaceutical company that seeks to enhance medical
options for both healthcare professionals and patients through
innovative solutions to unmet challenges. The company endeavors to
address unmet needs by optimizing the usefulness of proven
pharmaceutical therapies and delivering quality of life improvement
to patients. For additional information about Athena Bioscience,
LLC, please contact the company at 833-284-3622, or visit
athenabioscience.com.
- Kronish IM, Ye S. Adherence to cardiovascular medications:
lessons learned and future directions. Prog Cardiovasc Dis.
2013;55(6):590–600.
- DiMatteo MR, Giordani PJ, Lepper
HS, et al. Patient adherence and medical treatment outcomes: a
meta-analysis. Med Care. 2002;40(9):794–811.
- Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its
importance in cardiovascular outcomes. Circulation.
2009;119(23):3028–35
- Krousel-Wood M, Holt E, Joyce C, et al. Differences in
cardiovascular disease risk when antihypertensive medication
adherence is assessed by pharmacy fill versus self-report: the
Cohort Study of Medication Adherence among Older Adults (CoSMO) J
Hypertens. 2015;33(2):412–20.
View original
content:http://www.prnewswire.com/news-releases/tris-pharma-and-athena-bioscience-announce-exclusive-license-agreement-to-commercialize-near-to-market-long-acting-antihypertensive-product-in-the-us-301231828.html
SOURCE Tris Pharma, Inc.